Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
InFlectis BioScience logo — Harnessing expertise in cellular defense and drug discovery...

InFlectis BioScience

Harnessing expertise in cellular defense and drug discovery to develop molecules targeting misfolded protein disorders

Founded 2013 2-10 employees Grant Total: $9.34M Biopharma, Biotechnology +2

General Information

Company Name InFlectis BioScience
Founded Year 2013
Employees 2-10
Industries Biopharma, Biotechnology, Health Care +1
Funding Stage Grant
Social

Get notified when InFlectis BioScience moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About InFlectis BioScience

InFlectis BioScience is a biopharmaceutical startup dedicated to developing molecules targeting misfolded protein disorders. Leveraging their expertise in the cellular defense system and drug discovery, the company focuses on identifying and developing small molecules that modulate critical proteins involved in misfolded protein disorders. Founded in 2013, the company operates in the biopharma, biotechnology, healthcare, and pharmaceutical industries. The significance of Endoplasmic Reticulum (ER) proteostasis for cellular function and survival cannot be overstated. Disturbances in the ER's folding capacity can lead to the accumulation of unfolded or misfolded proteins, causing ER stress. In response to this, the mammalian ER employs a sophisticated machinery, known as the unfolded protein response (UPR), to maintain cellular integrity. In April 2024, InFlectis BioScience received a $649.60K grant investment from the National Multiple Sclerosis Society (NMSS), highlighting external validation and support for their groundbreaking work in combating misfolded protein disorders. With its innovative approach and strong industry presence, InFlectis BioScience exemplifies the potential for growth and impact in the biopharmaceutical sector.

Taxonomy: Cellular defense, Drug discovery, Protein misfolding disorders, Endoplasmic Reticulum (ER) proteostasis, Unfolded protein response (UPR), Misfolded protein disorders, Orphan diseases, Charcot-Marie-Tooth (CMT), Amyotrophic Lateral Sclerosis (ALS), Neuromuscular diseases, Inflammatory diseases, Integrated Stress Response (ISR) modulators, Clinical Stage, Small molecules

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Grant •••••• 1 •••• •••• 30 Apr 2024
Grant •••••• 1 •••• •••• 03 Jan 2024
Series A •••••• 4
Investor Investor Investor
•••• •••• 		03 Jun 2016
Seed Round •••••• 1
Investor
13 Jan 2015

InFlectis BioScience Alternatives & Competitors

InFlectis BioScience vs
Foldrx Pharmaceuticals
Foldrx Pharmaceuticals

FoldRx Pharmaceuticals is focused on discovering and developing disease-modifying drug therapies for...

Acquired
2 employees
InFlectis BioScience vs
VISTARA BIOSCIENCE
VISTARA BIOSCIENCE United States

Proteomic solutions for biomarker, target and drug candidate discovery and targeted degradation.

4 employees
Big Data, Biotechnology
InFlectis BioScience vs
Amyl Therapeutics
Amyl Therapeutics Belgium

Restoring clarity in amyloid diseases

Grant
9 employees
Biotechnology, Health Care

FAQ About InFlectis BioScience

Harnessing expertise in cellular defense and drug discovery to develop molecules targeting misfolded protein disorders
InFlectis BioScience was founded in 2013.
InFlectis BioScience operates in the following industries: Biopharma, Biotechnology, Health Care, Pharmaceutical.
InFlectis BioScience has approximately 2-10 employees.
InFlectis BioScience has completed 4 funding rounds, raising a total of $9.34M. The latest funding stage is Grant.
Top alternatives and competitors to InFlectis BioScience include Foldrx Pharmaceuticals, VISTARA BIOSCIENCE, Amyl Therapeutics, Treventis Corporation, Alector. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
InFlectis BioScience and Foldrx Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors InFlectis BioScience and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy